Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.

Presentation Details:

Date: December 5, 2024
Time: 10:30-10:55 am Eastern Time
Location: Lotte New York Palace, NY, NY

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

CONTACT:  

Monopar Therapeutics Inc.
Investor Relations  
Karthik Radhakrishnan
Chief Financial Officer  
[email protected]

Follow Monopar on social media for updates: 
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

You May Also Be Interested In

• JD.com’s 7Fresh Kitchen: “Chef Transformer” is coming！
• BRICS countries rally to counter shocks of power politics, unilateralism: China Daily editorial
• Cardano (ADA) Price Prediction: ADA Fights $0.20 as DigiTap Turns Everyday Card Spending Into TAP Rewards